Gene · 3612
IMPA1: inositol monophosphatase 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IMPA1: inositol monophosphatase 1. Genes, record 3612. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3612
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P29218 | Inositol monophosphatase 1 | 277 | 13 | Ensembl, GeneID, HGNC |
Source UniProt
Patents23
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 49876 | P29218 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1564 | P29218 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1564 | P29218 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 40477 | P29218 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 143448 | P29218 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 230311 | P29218 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 230311 | P29218 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 230311 | P29218 | Espacenet |
| WO 2013190075 A2 | 2013-12-27 | 753 | P29218 | Espacenet |
| US 8586006 B2 | 2013-11-19 | 9977 | P29218 | Espacenet |
1 to 10 of 23
See all 23 patentsDrugs3
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| LITHIUM CARBONATE | CHEMBL1200826 | Inositol-1(or 4)-monophosphatase 1 inhibitor | INHIBITOR | ChEMBL |
| LITHIUM CITRATE | CHEMBL2103738 | Inositol-1(or 4)-monophosphatase 1 inhibitor | INHIBITOR | ChEMBL |
| LITHIUM CITRATE ANHYDROUS | CHEMBL1201170 | Inositol-1(or 4)-monophosphatase 1 inhibitor | INHIBITOR | ChEMBL |
Trials87
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07540338 | LITHIUM CARBONATE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06789783 | LITHIUM CARBONATE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06424613 | LITHIUM CARBONATE | ClinicalTrials.gov | ||
| NCT06184581 | LITHIUM CARBONATE | PHASE4 | ClinicalTrials.gov | |
| NCT06008249 | LITHIUM CARBONATE | PHASE3 | ClinicalTrials.gov | |
| NCT05973786 | LITHIUM CARBONATE | PHASE3 | ClinicalTrials.gov | |
| NCT05923476 | LITHIUM CARBONATE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT05913947 | LITHIUM CARBONATE | PHASE4 | ClinicalTrials.gov | |
| NCT05814640 | LITHIUM CARBONATE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05618587 | LITHIUM CARBONATE | PHASE2 | 2025-03-05 | ClinicalTrials.gov |
1 to 10 of 87
See all 87 trialsNIH grants869
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IMPA1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P01AI120943 | Molecular Mechanisms of Filoviral-host Interactions | 4 | 2025 |
| P30CA056036 | Translational Research in Cancer | 4 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 4 | 2025 |
| R01AI072219 | Understanding B-Lactam Resistance in Acinetobacter baumannii | 4 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 3 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 3 | 2025 |
| R35GM140733 | Mechanism of Viral Genome Delivery into Cells | 3 | 2025 |
1 to 10 of 869Source NIH's project files
See all 869 nih grantsPapers1,792
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Alternative bipartite arrangements of VP1 BR1-3 drive efficient nuclear import of AAV2 capsids. | J Biol Chem | 2026 | 42749258 | PubTator, text mining | PubMed |
| Prevalence and clinical outcomes of Carbapenemase-Producing Enterobacterales (CPE) colonization in patients with solid organ malignancies: a prospective study. | Eur J Clin Microbiol Infect Dis | 2026 | 42711638 | PubTator, text mining | PubMed |
Characterization of resistance to last-line therapeutic molecules and genetic diversity of Klebsiella spp. strains involved in urinary tract infections in women: the case of Hôpital d'Instruction des Armées Omar Bongo Ondimba. | J Med Microbiol | 2026 | 42658193 | PubTator, text mining | PubMed |
| Rice Orange Leaf Phytoplasma Imp Protein Blocks G-M Interaction by Binding Glycoprotein G to Suppress Rice Stripe Mosaic Virus Infection. | Plant Cell Environ | 2026 | 42634277 | PubTator, text mining | PubMed |
| PlasmidRiskNet: An explainable machine-learning framework for antimicrobial resistance plasmid risk stratification. | New Microbes New Infect | 2026 | 42597927 | PubTator, text mining | PubMed |
| Teaching IMP (Impact, Meaning, Priorities): supporting meaningful psychosocial exploration and tailored management planning in GP training. | Educ Prim Care | 2026 | 42444034 | PubTator, text mining | PubMed |
| Corrigendum to "Nitazoxanide reverses pulmonary vascular remodeling in pulmonary hypertension by targeting the IMPA1-RAGE signaling axis" [Toxicology and Applied Pharmacology 507 (2026) 117657]. | Toxicol Appl Pharmacol | 2026 | 42392274 | PubTator, text mining | PubMed |
| Systematic surveillance of Carbapenemase-producing Enterobacterales reveals persistent spread of IMP-4 IncM2 plasmids in New Caledonia. | Commun Med (Lond) | 2026 | 42373753 | PubTator, text mining | PubMed |
| Identification of IMP-8-carrying Comamonas thiooxydans strains from a diarrheal sample: genomic insights into plasmid-borne carbapenemase in an environmental bacterium. | BMC Genomics | 2026 | 42363049 | PubTator, text mining | PubMed |
| Carbapenem-resistant Enterobacterales across the UK: A nationwide study of carbapenemase testing and novel antimicrobial activity. | Int J Antimicrob Agents | 2026 | 42362072 | PubTator, text mining | PubMed |
1 to 10 of 1,792
See all 1,792 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3612
GET https://conductscience.org/api/genes/v1/3612/patents?page=2